Bristol-Myers Squibb (BMY +1.8%) is out with results from a Phase 3 Attraction trial of Opdivo for patients with esophageal cancer.
The company says Opdivo demonstrated a 23%
reduction in the risk of death and 2.5-month improvement in median
overall survival compared to chemotherapy
BMY management is updating on the results at a
Presidential Symposium during the European Society for Medical Oncology
2019 Annual Congress.
Source: Press Release
https://seekingalpha.com/news/3502671-bristol-myers-higher-opdivo-update
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.